Cancer biotherapy
An introductory guide
Edited by Annie Young, Lewis Rowett, and David Kerr
Author Information
Edited by Annie Young, Nurse Director, Three Counties Cancer Network, St Paul's Medical Centre, Cheltenham, UK, Lewis Rowett, Executive Editor, Annals of Oncology, ESMO Head Offce, Viganello-Lugano, Switzerland, and David Kerr, Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics, University of Oxford; Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford, UK
Contributors:
Kenneth D Bagshawe, Department of Medical Oncology, Imperial College, London, UK
Richard H J Begent, Department of Oncology, University College London, UK
Deborah Beirne, Cancer Medicine Research Unit, St James Hospital, Leeds, UK
Peter Borchmann, Medizinische Einrichtungen der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany
Aniruddha Choudhury, Immune and Gene Therapy Laboratory, Karolinska University Hospital, Stockholm, Sweden
Andreas Engert, Medizinische Einrichtungen der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany
David Kerr, Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford, UK
Dirk Laurent, Schering AG, SBU Specialized Therapeutics, Corporate Clinical Development Therapeutics Europe, Berlin, Germany
Wan-Teck Lim, National Cancer Centre Singapore, Republic of Singapore
Howard L McLeod, Washington University School of Medicine, St Louis, Missouri, USA
Håkan Mellstedt, Departments of Oncology and Hematology, Karolinska University Hospital, Stockholm, Sweden
Rachel Midgley, Cancer Research UK, Churchill Hospital, Oxford, UK
Monica M Mita, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
Kees Nooter, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Cornelius J A Punt, Department of Medical Oncology. Radboud University Medical Centre Nijmegen, The Netherlands
Lewis Rowett, Annals of Oncology, ESMO Head Office, Viganello-Lugano, Switzerland
Eric K Rowinsky, Imclone Systems, Branchburg, New Jersey, USA
Gary K Schwartz, Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, USA
Leonard Seymour, Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, UK
Manish A Shah, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
Surinder K Sharma, Department of Oncology, University College London, UK
Stefan Sleijfer, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Neil Steven, CRC Institute for Cancer Studies, The Medical School, University of Birmingham, UK
Archie Tse, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA
Carla M L van Herpen, Department of Medical Oncology. Radboud University Medical Centre Nijmegen, The Netherlands
Jaap Verwejj, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Annie Young, Three Counties Cancer Network, Cheltenham, UK
